Mainstream

Insmed Targets $405m $425m Arikayce Revenue For 2025 While Advancing Brensocatib And Tpip Programs

Insmed targets $405M-$425M ARIKAYCE revenue for 2025 while advancing brensocatib and TPIP programs

Insmed targets $405M-$425M ARIKAYCE revenue for 2025 while advancing brensocatib and TPIP programs

Post ContentinsmRead More

You might also be interested in reading JPMorgan’s Blockchain Arm Kinexys Tests Tokenized Carbon Credits With S&P Global.

February 20, 2025
In Mainstream